CAR-T Therapy in China

Yes. International patients have the legal right to seek medical treatment in China. Hospitals that treat international patients are licensed by NMPA, and access is granted either through approved commercial products or through registered clinical trials and IITs. Legality is not the issue; eligibility is.

No. Most Chinese CAR-T products are approved by NMPA for domestic use, but are not FDA-approved for the US market. They are accessed either as commercial products inside China or via registered trials. This distinction matters: a product that is legal and standard-of-care in China may not be available, reimbursed, or approved in your home country.

You can express a preference, but final matching is driven by cancer type, prior treatment history, and the protocol's inclusion/exclusion criteria as decided by the principal investigator. A hospital that is excellent for lymphoma CAR-T may not run the trial your case needs. The honest sequence is: clinical fit first, hospital preference second.

Grade 3A hospitals that run CAR-T programs generally have ICU teams trained to manage CRS and ICANS. Before you commit, ask the hospital in writing: how many grade 3–4 CRS cases have you managed in the last 12 months, what is your tocilizumab availability, and what is your neuro-critical care pathway. A hospital that cannot answer these questions in writing is a red flag.

It depends on the route. On the trial and IIT route, the investigational drug is usually covered by the sponsor, so the patient's cost is ancillary care. On the commercial route, the drug is paid by the patient or private insurance, and pricing varies by product and by hospital. The NMPA label and the hospital's international department are the authoritative sources — not third-party estimates.

Plan for four to eight weeks in total: one to two weeks for screening, two to four weeks for leukapheresis and manufacturing, two to four weeks for infusion and monitoring. Commercial products with simpler monitoring requirements can sometimes be delivered in a shorter window. Trials with extended observation windows can take longer.

English records are accepted by most international departments, but critical documents — pathology reports, molecular testing, prior treatment summaries — must be translated into Chinese for the treating team. Confirm in writing who translates, to what standard, and whether the hospital accepts the translation you provide. Do not rely on a family member for consent or complication discussions.

This should be discussed before travel. Ask the hospital in writing: what is the response rate for my cancer type and stage in this specific protocol, what happens if I do not respond, and what alternative options — including bridging therapy, a second CAR-T, or palliative care — are available in China or at home. A hospital that refuses to answer in writing is a red flag.